Business Description
Redhill Biopharma Ltd
NAICS : 325412
ISIN : US7574681034
Share Class Description:
RDHL: ADRDescription
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.75 | |||||
| Equity-to-Asset | 0.09 | |||||
| Debt-to-Equity | 0.57 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 0.21 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -9.6 | |||||
| Beneish M-Score | 1.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -75.7 | |||||
| 3-Year FCF Growth Rate | 63.3 | |||||
| 3-Year Book Growth Rate | -80.6 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.81 | |||||
| 9-Day RSI | 21.22 | |||||
| 14-Day RSI | 28.92 | |||||
| 6-1 Month Momentum % | 64.63 | |||||
| 12-1 Month Momentum % | -83.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.84 | |||||
| Quick Ratio | 0.61 | |||||
| Cash Ratio | 0.29 | |||||
| Days Inventory | 116.79 | |||||
| Days Sales Outstanding | 119.65 | |||||
| Days Payable | 66.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -173.7 | |||||
| Shareholder Yield % | 118.48 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 42.74 | |||||
| Operating Margin % | 21.31 | |||||
| Net Margin % | 32.37 | |||||
| FCF Margin % | -73.43 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 16.78 | |||||
| ROIC % | 8.96 | |||||
| ROC (Joel Greenblatt) % | 1095.96 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 1.05 | |||||
| PS Ratio | 0.02 | |||||
| PB Ratio | 3.37 | |||||
| EV-to-EBIT | 0.18 | |||||
| EV-to-EBITDA | 0.08 | |||||
| EV-to-Forward-EBITDA | -3.75 | |||||
| EV-to-Revenue | 0.24 | |||||
| EV-to-Forward-Revenue | 1.37 | |||||
| EV-to-FCF | -0.32 | |||||
| Earnings Yield (Greenblatt) % | 555.56 | |||||
| FCF Yield % | -221.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RDHL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Redhill Biopharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 35.745 | ||
| EPS (TTM) ($) | -3.807 | ||
| Beta | 5.52 | ||
| Volatility % | 380.55 | ||
| 14-Day RSI | 28.92 | ||
| 14-Day ATR ($) | 0.038617 | ||
| 20-Day SMA ($) | 0.5006 | ||
| 12-1 Month Momentum % | -83.59 | ||
| 52-Week Range ($) | 0.257 - 3.6 | ||
| Shares Outstanding (Mil) | 31.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Redhill Biopharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Redhill Biopharma Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Redhill Biopharma Ltd Frequently Asked Questions
What is Redhill Biopharma Ltd(RDHL)'s stock price today?
The current price of RDHL is $0.37. The 52 week high of RDHL is $3.60 and 52 week low is $0.26.
When is next earnings date of Redhill Biopharma Ltd(RDHL)?
The next earnings date of Redhill Biopharma Ltd(RDHL) is 2024-04-26 Est..
Does Redhill Biopharma Ltd(RDHL) pay dividends? If so, how much?
Redhill Biopharma Ltd(RDHL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers